AGIO -12%—shareholder lawsuits filed—on phase-2 data in pyruvate-kinase deficiency: http://www.fool.com/investing/2016/12/05/why-agios-pharmaceuticals-inc-stock-fell-sharply-t.aspx Updated data from DRIVE PK with additional patients and longer follow-up demonstrate that 47% of all efficacy evaluable patients (n=15/32) and 58% of evaluable patients with at least 1 missense mutation (n=15/26) treated with AG-348 experienced a maximum hemoglobin (Hb) increase from baseline of >1.0 gram per deciliter (g/dL). These response rates are lower than the previously reported numbers for this trial (when n was smaller).